Innovative AI Advances Risk Profiling for HER2+ Breast Cancer Patients

Enhancing Breast Cancer Care with AI: Insights from Project EVOLVE

In recent research advancements, Novellia, a pioneering AI-driven health data company, has made significant strides in optimizing risk profiling for patients undergoing treatment for HER2-positive (HER2+) breast cancer. This innovative research, named Project EVOLVE, aims to bridge the gap between patient experiences and precision healthcare by utilizing AI to analyze health records and integrating specific educational interventions. The findings from this comprehensive study shed light on how real-world patient data can enhance understanding and management of serious adverse events, particularly interstitial lung disease (ILD), which is connected to certain breast cancer therapies.

Understanding the Context: HER2+ Breast Cancer Treatments

HER2+ breast cancer treatments have revolutionized outcomes for many patients, yet they come with potential adverse effects that require heightened awareness among healthcare providers. ILD is one such serious concern that can emerge during the treatment process, prompting the need for effective monitoring and risk assessment. Project EVOLVE was meticulously designed to investigate the incidence of ILD and its early warning signs using longitudinal patient records.

In a meticulous two-part observational study supported by Daiichi Sankyo and AstraZeneca, 38 patients diagnosed with HER2+ breast cancer were recruited through breast cancer advocacy groups. These participants consented to join Novellia's advanced health record platform, which analyzed over half a million unique health records to gather critical insights about respiratory adverse events.

Key Findings of Project EVOLVE

The analysis revealed some remarkable statistics. Only 4.17% of respiratory adverse events among participants were diagnosed as ILD, a stark contrast to the 10-14% incidence reported in existing literature. The majority of respiratory issues identified included asthma (37.5%), common colds (20.8%), and COVID-19 (8.3%). These insights indicate a potential discrepancy between clinical trial data and real-world patient experiences.

In the second phase of the study, healthcare providers (HCPs) totaling 275 individuals participated in targeted educational interventions tailored to the new findings from Novellia's analysis. Results exhibited significant improvements in HCP confidence regarding treatment decisions, with confidence levels increasing from 66% to 90%. Furthermore, knowledge and confidence in managing adverse events surged from 69% to an impressive 92%. In parallel, educational initiatives for the patients themselves resulted in a similar rise in confidence concerning treatment adherence (72% to 89%) and managing side effects at home (55% to 79%).

Implications for Future Breast Cancer Care

Shashi Shankar, CEO of Novellia, commented on the importance of these findings, asserting, "Project EVOLVE answers how insights derived from personal health records can support and inform patient care, specifically enhancing risk profiling for serious adverse events in HER2+ breast cancer patients." These results highlight the potential of Novellia's methodology to advance early detection strategies and improve patient outcomes through data-informed education strategies tailored for both patients and healthcare providers.

Moreover, Steve Olsen, MD, PhD, a medical advisor for Novellia, emphasized the breakthrough nature of this project. He noted, "This novel approach leveraging patient-authorized records has the potential to efficiently identify clinical features predisposing patients to adverse events and guide treatment strategies to prioritize patient safety and treatment efficacy."

Conclusion

As Project EVOLVE prepares for its poster presentation at the 2024 San Antonio Breast Cancer Symposium, the research embodies an inspiring model for future studies aimed at harmonizing patient experiences with advanced data analytics. Through initiatives like these, the healthcare industry continues to evolve toward a more adaptive and personalized approach to cancer treatment, ultimately aiming for better patient care and outcomes.

To explore more about Novellia and its transformative approach to patient data, visit Novellia.